Methylation Patterns of the NUPR1, MGMT, NDRG2, and GLI1 Genes and Their Impact on Therapeutic Outcome of GBM Patients

Plain-language summary

This study examines the methylation patterns of the NUPR1, MGMT, NDRG2 and GLI1 genes and their impact on treatment outcomes in glioblastoma (GBM) patients. It included adult patients over 18 with a recent GBM diagnosis. It was a study with no assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Ain Shams University

Intervention

DNA methylation profiling

Start date

9/1/2020

Estimated completion

12/9/2022

Countries

Egypt

Related genes

Locations

• Cairo, Egypt

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Adult patients (age \> 18 years)
* Recent diagnosis of GBM
* Performance status of less than or equal to 2 on the Ester Clinical Oncology Group
* (ECOG) scale,1)
* Pathologically proven GBM

Exclusion Criteria:

* Other types of cancer,
* HBV
* HCV
* Schistosomiasis
* HCC
* HIV
* Alcohol intake
* Thyroid dysfunction
* Inflammatory diseases
* Cerebrovascular disorders